324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
The Readout Loud
00:00
Withdrawal Woes: A Sickle Cell Drug's Fate
This chapter examines the controversial withdrawal of a sickle cell disease drug by a major pharmaceutical company due to safety concerns raised by regulators. It highlights the implications for future drug approvals and the effectiveness of oversight from the FDA compared to European authorities.
Transcript
Play full episode
